FDA approves reslizumab to treat severe asthma – Pharmacy Today, American Pharmacists Association, pharmacist.com


Medscape

FDA approves reslizumab to treat severe asthma
Pharmacy Today, American Pharmacists Association, pharmacist.com
FDA has cleared reslizumab (Cinqair—Teva) for use with other asthma medicines for the maintenance treatment of severe asthma in adults. The drug is indicated for patients with a history of severe asthma attacks despite using their current asthma …
FDA approves Cinqair to treat severe asthmaFDA.gov
Reslizumab (Cinqair) Approved to Treat Severe AsthmaMedscape
FDA Approves Teva's Asthma Injection to Treat Severe AsthmaNews Every day
Globes –UPI.com
all 55 news articles »

View full post on asthma – Google News

FDA approves Cinqair to treat severe asthma – FDA.gov


Medscape

FDA approves Cinqair to treat severe asthma
FDA.gov
The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of …
Reslizumab (Cinqair) Approved to Treat Severe AsthmaMedscape
FDA Approves Reslizumab for Adults With Severe AsthmaMedPage Today
FDA clears Teva's asthma med CinqairSeeking Alpha
Monthly Prescribing Reference (registration)
all 25 news articles »

View full post on asthma – Google News

Potential Target for Severe Asthma, Other Chronic Inflammatory Diseases Identified – Lung Disease News


Lung Disease News

Potential Target for Severe Asthma, Other Chronic Inflammatory Diseases Identified
Lung Disease News
From previous research it was known that Dkk-1, a protein produced by platelets (blood cells responsible for clotting), inhibits tissue repair, a feature that is common in chronic inflammatory disorders such as asthma, autoimmune diseases and cancer

View full post on asthma – Google News

Study identifies new target for severe asthma, chronic inflammatory diseases – Medical Xpress


Medical Xpress

Study identifies new target for severe asthma, chronic inflammatory diseases
Medical Xpress
Chronic inflammation is commonly found in asthma, autoimmune diseases, cancer, and viral infections, and it's characterized by constant activation of platelets with unhealed tissue damage. Scientists who have studied the Dkk-1 protein were aware that

View full post on asthma – Google News

The epidemiology of asthma and its comorbidities in Poland – Health problems of patients with severe asthma as evidenced in the Province of Lodz.

Related Articles

The epidemiology of asthma and its comorbidities in Poland – Health problems of patients with severe asthma as evidenced in the Province of Lodz.

Respir Med. 2016 Jan 20;

Authors: Panek M, Mokros ?, Pietras T, Kuna P

Abstract
INTRODUCTION: Population studies supply interesting data regarding the epidemiology, comorbidity and risk factors of asthma, which have direct clinical implications for patients.
OBJECTIVES: The aim of the work was to evaluate the degree of severity of asthma in the studied group, the levels of anti-asthma treatment, the prevalence of asthma comorbidities and their influence on the clinical course of the illness.
PATIENTS AND METHODS: The study encompassed 451 participants: 52.11% were asthma patients (study group) and 47.89% were healthy subjects (controls). Respiratory function tests, ACT™ test and skin prick tests were performed.
RESULTS: Asthma severity was mild in 14.89%, moderate in 49.36% and severe in 35.74%. Oral GCS were used by 29%, inhalers 44%, LABA 68%, SABA 67%, LAMA 6%, SAMA 14% and MX 16%. Rhinitis and allergy were significantly more common in patients. GERD and neurological diseases were risk factors for asthma, and GERD significantly intensified the risk of severe asthma. GERD, atherosclerosis, hypertension, ischaemic heart disease and other cardiac diseases, lipid disorders, COPD, and the presence of any neoplastic disease significantly worsened the degree of asthma control.
DISCUSSION: Severe asthma was a significant clinical issue in over 35% of cases. The most commonly-used group of drugs were LABAs, while inhaled GCS and LAMA were uncommon, especially among severe cases. A significant problem was the high percentage of systemic GCS used by severe cases. The most important risk factor for asthma, including its severe form, is GERD. Numerous comorbid conditions significantly worsen the degree of asthma control.

PMID: 26852088 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Severe asthma linked to insomnia, sleep duration, and sleep hygiene in adolescents – Bel Marra Health


Bel Marra Health

Severe asthma linked to insomnia, sleep duration, and sleep hygiene in adolescents
Bel Marra Health
severe-asthma-linked-to-insomnia-sleep-duration-and- Severe asthma is linked to insomnia, sleep duration, and sleep hygiene in adolescents. The findings were published in The Journal of Allergy and Clinical Immunology: In Practice. The researchers …

View full post on asthma – Google News

New treatment for severe asthma – Pharmacy Today, American Pharmacists Association, pharmacist.com

New treatment for severe asthma
Pharmacy Today, American Pharmacists Association, pharmacist.com
In early November, FDA approved mepolizumab (Nucala—GlaxoSmithKline), a novel treatment for severe asthma. This new treatment is an interleukin-5 (IL-5) antagonist that works by inhibiting IL-5 signaling, with subsequent reduction in the production

View full post on asthma – Google News